Physician profile
Sandra D Elder
NPI 1538122668
$8,004.48
in general payments reported to CMS, 2019-2025
39 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $310 · 2021: $987 · 2022: $1,181 · 2023: $1,574 · 2024: $1,582 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,291 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,290.72 |
| Education | $366.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $944.67 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $634.68 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $523.29 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $485.76 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $445.98 | 2019-2025 | |
| Leo Pharma INC. | $436.91 | 2019-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $399.63 | 2019-2025 | Winlevi, Odomzo, Blu-U |
| Amgen INC. | $358.91 | 2021-2025 | Otezla |
| Incyte Corporation | $350.53 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $334.33 | 2022-2023 | Tremfya, Simponi, Remicade |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $305.39 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Genzyme Corporation | $278.37 | 2020-2025 | |
| Galderma Laboratories, L.P. | $243.38 | 2019-2025 | Nemluvio |
| Merz North America, INC. | $241.84 | 2019-2024 | |
| Journey Medical Corporation | $229.70 | 2019-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.